These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33992120)

  • 1. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.
    Feng LY; Huang YZ; Zhang W; Li L
    J Ovarian Res; 2021 May; 14(1):67. PubMed ID: 33992120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
    Feng LY; Yan BB; Huang YZ; Li L
    Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and bioinformatics analysis of the relationship between LAMA3 DNA methylation expression and platinum resistance and prognosis in epithelial ovarian cancer].
    Chen CX; Zhang YL; Huang YZ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2024 Jun; 59(6):454-464. PubMed ID: 38951081
    [No Abstract]   [Full Text] [Related]  

  • 4. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
    Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
    Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
    Sung HY; Yang SD; Park AK; Ju W; Ahn JH
    Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
    Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
    Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
    Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
    J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.
    Lund RJ; Huhtinen K; Salmi J; Rantala J; Nguyen EV; Moulder R; Goodlett DR; Lahesmaa R; Carpén O
    Sci Rep; 2017 May; 7(1):1469. PubMed ID: 28473707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands.
    Dai W; Teodoridis JM; Graham J; Zeller C; Huang TH; Yan P; Vass JK; Brown R; Paul J
    BMC Bioinformatics; 2008 Aug; 9():337. PubMed ID: 18691414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
    Flanagan JM; Wilson A; Koo C; Masrour N; Gallon J; Loomis E; Flower K; Wilhelm-Benartzi C; Hergovich A; Cunnea P; Gabra H; Braicu EI; Sehouli J; Darb-Esfahani S; Vanderstichele A; Vergote I; Kreuzinger C; Castillo-Tong DC; Wisman GBA; Berns EM; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2017 May; 23(9):2213-2222. PubMed ID: 27663594
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
    Vaclavikova R; Klajic J; Brynychova V; Elsnerova K; Alnaes GIG; Tost J; Kristensen VN; Rob L; Kodet R; Skapa P; Mrhalova M; Soucek P
    Oncol Rep; 2019 Aug; 42(2):763-774. PubMed ID: 31173253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.
    Burton ER; Gaffar A; Lee SJ; Adeshuko F; Whitney KD; Chung JY; Hewitt SM; Huang GS; Goldberg GL; Libutti SK; Kwon M
    Mol Cancer Res; 2011 Aug; 9(8):1126-38. PubMed ID: 21693594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [E-cadherin promoter methylation and demethylation in epithelial ovarian carcinoma cells].
    Qu PP; Shi Z; Li N
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):538-41. PubMed ID: 19957556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
    Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.